Japanese API Manufacturer Hit with Warning, US Import Alert after Gross Violations

By Zachary Brennan

- Last updated on GMT

Related tags Manufacturing Fda

Japanese API Manufacturer Hit with US Import Alert after Violations
The US FDA has reprimanded and halted all imports from Japanese API manufacturer Asada Milling Co. after finding its manufacturing equipment “corroded, rusted, chipped of paint, and coated with an unidentified white powder,” the agency said in its warning letter.

The FDA’s inspection from October 2012 found “visible powder​” on the equipment, floors, and walls of the facility that “could lead to a cross-contamination​” of the two types of APIs manufactured at the Gunma-based facility. Hundreds of insects were also observed by FDA inspectors in the insect catchers located in the processing areas of the facility. 

Meanwhile, Asada also failed to establish procedures “to review process validation, change management documentation, release of raw materials, and to approve or reject batch records. Moreover, your firm failed to ensure the use of an effective system for calibrating critical manufacturing equipment and to provide employees with CGMP training​,” the FDA said.  

In terms of the raw materials Asada uses to make its APIs, the FDA found the company failed to perform identity testing on them and failed to verify the reliability of certificates of analysis for these raw materials at appropriate intervals.  

Representatives from Asada also told FDA inspectors that the company has no stability program for any of the APIs produced at the facility or any data to support the expiration date provided on the label for its products. 

The quality unit’s failure “to review, release, or reject finished API products​,” and its failure “to perform annual product quality reviews​” were also called out in the letter.

In addition to the warning letter, the FDA has recently put the company on import alert​, which means their products are not allowed to be shipped to the US. Asada did not respond to a request for comment by press time.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars